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Nitroheterocyclic drugs cure 
experimental Trypanosoma cruzi 
infections more effectively in the 
chronic stage than in the acute 
stage
Amanda Fortes Francisco1, Shiromani Jayawardhana1, Michael D. Lewis1, Karen L. White3, 
David M. Shackleford3, Gong Chen3, Jessica Saunders3, Maria Osuna-Cabello4, Kevin D. Read4, 
Susan A. Charman3, Eric Chatelain2 & John M. Kelly1
The insect-transmitted protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease, 
and infects 5–8 million people in Latin America. Chagas disease is characterised by an acute phase, 
which is partially resolved by the immune system, but then develops as a chronic life-long infection. 
There is a consensus that the front-line drugs benznidazole and nifurtimox are more effective against 
the acute stage in both clinical and experimental settings. However, confirmative studies have been 
restricted by difficulties in demonstrating sterile parasitological cure. Here, we describe a systematic 
study of nitroheterocyclic drug efficacy using highly sensitive bioluminescence imaging of murine 
infections. Unexpectedly, we find both drugs are more effective at curing chronic infections, judged 
by treatment duration and therapeutic dose. This was not associated with factors that differentially 
influence plasma drug concentrations in the two disease stages. We also observed that fexinidazole 
and fexinidazole sulfone are more effective than benznidazole and nifurtimox as curative treatments, 
particularly for acute stage infections, most likely as a result of the higher and more prolonged exposure 
of the sulfone derivative. If these findings are translatable to human patients, they will have important 
implications for treatment strategies.
Chagas disease is caused by the insect-transmitted protozoan Trypanosoma cruzi and is the most important para-
sitic infection in Latin America, affecting 5–8 million people1. It is also becoming a global problem, with increas-
ing numbers of symptomatic cases in non-endemic areas, including the USA and Europe2,3. The initial acute 
stage of Chagas disease is usually relatively mild, although in children it can be severe, and sometimes fatal. With 
the development of a cellular immune response, parasitemia is suppressed, but sterile immunity is not achieved. 
Initially, the chronic infection phase is asymptomatic, but ~30% of patients eventually develop pathology, often 
decades later. Cardiomyopathy occurs in the majority of these individuals, whilst a minority suffer digestive tract 
megasyndromes4,5.
The nitroheterocyclic compounds benznidazole and nifurtimox are the front-line Chagas disease drugs6,7. 
Unfortunately, they display a range of toxic side-effects, which can impact negatively on patient compli-
ance. Furthermore, both require bioactivation by the same parasite nitroreductase, a potential source of 
cross-resistance8,9. Treatment failures are common and new drugs are urgently required. Recent clinical trials 
have had disappointing outcomes. Posaconazole, a potent ergosterol biosynthesis inhibitor, was found to display 
limited curative potential against chronic infections10, and benznidazole, although partially11 or highly10 effective 
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at achieving parasitological cure, showed no significant benefit in patients who had already developed advanced 
chagasic cardiomyopathy11.
There is general consensus that nitroheterocylic drugs are more effective against T. cruzi infections during 
the acute stage than in the chronic stage. Although widely quoted12–21, there have been few systematic studies 
to support this assertion. One of the major problems has been the difficulty in unequivocally demonstrating 
sterile cure, both in human patients and animal models. To increase the accuracy and reproducibility of drug 
testing, we developed highly sensitive bioluminescence methodology based on the expression by trypanosomes 
of a red-shifted luciferase reporter22–24. This in vivo imaging procedure has a limit of detection of 100–1000 par-
asites, and facilitates the real-time tracking of parasite burden in individual mice during long-term experimental 
infections. With the T. cruzi CL Brener-BALB/c mouse-parasite combination, the parasite burden peaks 14 days 
post-infection, and then resolves to the chronic phase over the next 30–40 days23. Infections persist for at least a 
year in dynamic equilibrium, at levels 2–3 orders of magnitude below the acute stage. Parasites are pan-tropic in 
the acute stage, but in chronically infected mice, the large intestine and stomach are the primary reservoir sites, a 
feature that also occurs for other parasite-mouse genotype combinations. Transient bioluminescent foci can also 
be detected at peripheral sites during chronic infections, which fluctuate in a spatiotemporally dynamic manner, 
appearing and disappearing over a period of hours. This bioluminescence imaging system is more reliable than 
PCR-based approaches for tracking experimental T. cruzi infections and for confirming parasitological cure25.
Here, we describe the use of this predictive model to undertake a detailed comparison of the efficacy of the 
nitroheterocyclic agents benznidazole, nifurtimox, fexinidazole and fexindazole sulfone against acute and chronic 
T. cruzi infections.
Results
Nitroheterocyclic drugs cure chronic stage infections more effectively than acute stage infec-
tions. Using the T. cruzi CL Brener-BALB/c model, we found that chronic infections could be cured with 5 
daily oral doses of 100 mg kg−1 benznidazole (ref. 25, Table 1, Fig. 1a). Drug efficacy was assessed by both in vivo 
and ex vivo imaging, with cyclophosphamide-induced immunosuppression to enhance the reactivation of any 
residual infection (Methods). When we applied this same treatment regimen to mice at the peak of the acute 
stage, none of the 30 mice tested were cured (Table 1, Fig. 1b). Although treatment initiated 14 days post-infection 
resulted in a rapid drop in the bioluminescence-inferred parasite burden, this was transient, with a rapid return 
to levels similar to those in non-treated mice. Treatment of acute stage infections had to be extended to 20 days to 
achieve curative outcomes comparable to 5 days treatment in the chronic stage (Table 1).
Using the 5 day protocol, we also found nifurtimox to be highly effective at curing chronic infections, with 
9/10 mice remaining bioluminescence negative after immunosuppression (Fig. 1a). In contrast, non-curative 
T. cruzi CL Brener strain 
Chronic Infection Cure Rate Acute Infection Cure Rate
Treatment length Treatment length
Drug
Mouse 
strain
Dose  
(mg kg−1) 5 days 10 days 20 days 5 days 10 days 20 days
BZ BALB/c 10 qd — 0% (0/6) 17% (1/6) — 0% (0/6) 0% (0/6)
BALB/c 30 qd 0% (0/6) 67% (4/6) 100% (6/6) — 0% (0/6) 33% (2/6)
BALB/c 100 qd 100% (11/11)* 100%(15/15)* 100%(11/11)* 0% (0/30) 0% (0/6) 93%(14/15)
 BALB/c 50 bid — 100% (6/6) — 0% (0/6) — —
NF BALB/c 30 qd 33% (2/6) 83% (5/6) — — — —
BALB/c 100 qd 90% (9/10) — — 0% (0/6) 17 (1/6) —
BALB/c 50 bid — — — 17% (1/6) — —
FX BALB/c 30 qd 50% (3/6) 100% (6/6) — — — —
BALB/c 100 qd 100% (8/8) — — 67% (4/6) 100 (6/6) —
BALB/c 50 bid — — — 100% (6/6) — —
FXS BALB/c 30 qd 17% (1/6) 100% (6/6) — 0% (0/6) — —
BALB/c 50 qd 100% (6/6) — — 0% (0/6) — —
BALB/c 100 qd 100% (7/7) — — 100%(15/15) — —
 BALB/c 50 bid — — — 83% (5/6) — —
T. cruzi JR strain
BZ BALB/c 100 qd — — — 0% (0/6) — —
C3H 100 qd 60% (3/5) — — 0% (0/5) — —
FXS BALB/c 100 qd — — — 80% (4/5) — —
 C3H 100 qd 100% (5/5) — — 80% (4/5) — —
Table 1.  Nitroheterocyclic drug efficacy in BALB/c and C3H mice infected with Trypanosoma cruzi CL 
Brener and JR strains. *includes data reported previously in ref. 25 qd; quaque die (once daily), bid; bis in die 
(twice daily). Following treatment, mice in the acute or chronic stage were monitored by bioluminescence 
imaging (Methods, Figs 1, 2, 3 and 4). Mice were only designated as cured if they were bioluminescence 
negative by both in vivo and ex vivo imaging, following immunosuppressive treatment. BZ = benznidazole; 
NF = nifurtimox; FX = fexinidazole; FXS = fexinidazole sulfone.
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outcomes were observed in all cases when acute stage infections were treated with 100 mg kg−1 nifurtimox 
(Table 1, Fig. 1b). Therefore, with the 5 day treatment protocol, both of the front-line Chagas disease drugs are 
more effective against experimental infections in the chronic stage.
We next tested fexnidazole and its metabolite fexinidazole sulfone. Previous studies suggested that these nitro-
imidazoles might have greater in vivo activity than benznidazole26,27. When chronically infected mice were treated 
for 5 days with oral doses of 100 mg kg−1, there was a 100% cure rate in each case (Table 1, Fig. 1a). A similar 
outcome was observed when acute stage infections were treated with fexinidazole sulfone (Fig. 1b,c). Fexinidazole 
also showed significant efficacy during acute stage infections, curing 4/6 mice.
To further explore the 5 day treatment protocol for acute stage infections, we administered nitroheterocyclic 
drugs as two daily doses of 50 mg kg−1. With this schedule, benznidazole again failed to cure any mice (0/6) 
(Table 1, Fig. 2). Nifurtimox was more effective at reducing parasite burden, but only 1/6 mice was ultimately 
cured. In contrast, fexinidazole treatment was 100% successful (6/6) and fexinidazole sulfone curative in 5/6 cases. 
Fexinidazole sulfone was then investigated by administering single doses of 50 mg kg−1 for 5 days. With chronic 
stage infections, all 6 mice were cured. In contrast, none were cured when acute stage infections were treated, 
confirming the differential effectiveness of nitroheterocyclic drugs against the two disease stages (Table 1).
When chronically infected mice were treated daily with 30 mg kg−1 benznidazole for 20 days, there was a 100% 
cure rate (6/6) (Table 1, Fig. 3a). Against acute stage infections however, the 30 mg kg−1 dosing regimen was less 
effective, with only 2/6 mice cured (Fig. 3b). This stage-specific trend was also observed when treatment duration 
was reduced to 10 days; 4/6 chronically infected mice were cured, compared to 100% treatment failure (0/6) in the 
Figure 1. Treatment of chronic (a) and acute (b) stage Trypanosoma cruzi infections with nitroheterocyclic 
drugs assessed by in vivo imaging. BALB/c mice, infected with bioluminescent CL Brener parasites, were treated 
once daily by oral gavage for 5 days at 100 mg kg−1 with benznidazole (BZ), nifurtimox (NF), fexinidazole (FX), 
or fexinidazole sulfone (FXS). Treatment was initiated 114 days (chronic) or 14 days (acute) post-infection (see 
Table 1 for numbers of mice). Representative ventral images of 2 mice are shown for each drug, at various points 
post-infection. NT, non-treated (vehicle only). Mice with low/background levels of bioluminescence were 
immunosuppressed by cyclophosphamide (Methods), starting 135 or 31 days post-infection and are underlined 
with a red bar. All acute stage mice treated with BZ or NF were non-cured, and only immunosuppressed 
where necessary to confirm outcome. In acute stage infections, examples of both curative and non-curative 
outcomes with FX are shown. (c) Assessment of drug activity against acute stage infections by ex vivo imaging. 
Representative images of organs/tissues isolated 50 days post-infection (Methods) from NT (i), FX-treated (ii) 
and FXS-treated (iii) mice are shown. The locations of specific organs/tissues are illustrated in the left-hand 
image. The heat-map is on a log10 scale and indicates intensity of bioluminescence from low (blue) to high 
(red); the minimum and maximum radiances for the pseudocolour scale are shown.
www.nature.com/scientificreports/
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acute stage (Table 1, Fig. 3a,b). When 5 days treatment was assessed, we found that benznidazole could reduce bio-
luminescence to background levels in most chronically infected mice, but the effect was transient and the parasite 
burden rebounded, particularly after immunosuppression. In this model therefore, daily dosing with 30 mg kg−1 
benznidazole is more effective against chronic than acute stage infections, with the duration of treatment being a 
major factor in determining outcome. Treatment of chronic infections for 20 days with doses as low as 10 mg kg−1 
also resulted in a significant reduction in parasite burden, although in this case, only 1 out of 6 mice was ultimately 
cured (Table 1). Nifurtimox, fexinidazole and fexinidazole sulfone displayed significant activity at 30 mg kg−1  
against chronic stage infections. For example, 10 days treatment of chronic infections with 30 mg kg−1 nifurtimox 
produced a higher cure rate (5/6) than 10 days treatment of acute stage infections with 100 mg kg−1 (1/6). As with 
benznidazole, restricting the treatment period to 5 days, reduced drug efficacy in all cases (Table 1).
Greater efficacy against chronic stage infections is not a model-specific phenomenon. We 
investigated if our observations were relevant to other experimental models of Chagas disease. First, we assessed 
whether fexinidazole sulfone was also more effective than benznidazole in BALB/c mice infected with the JR 
strain of T. cruzi. The CL Brener (lineage TcVI) and JR (lineage TcI) strains are highly divergent28, although both 
strains display similar infection profiles in a BALB/c background when monitored by bioluminescence imaging29. 
Treatment of acute stage infections with 100 mg kg−1 benznidazole for 5 days resulted in a rapid knockdown 
in bioluminescence (Fig. 4a, Table 1). However, as with CL Brener infections, this effect was transient and 
non-curative (Figs 1b and 4a). When JR-infected BALB/c mice were treated with fexinidazole sulfone using the 
same dosing regimen, all but one of the mice were successfully cured (Fig. 4a). Therefore, at similar doses, fex-
inidazole sulfone is more effective than benznidazole as a treatment for acute stage infections in two diverse 
T. cruzi strains.
We next examined the efficacy of both drugs in C3H mice. In this strain, the parasite burden is typically higher 
and more disseminated than in BALB/c mice29. When acute stage JR-infections were assessed following 5 days 
treatment (100 mg kg−1), the outcomes were similar to those in the BALB/c strain, with 100% treatment failure in 
the case of benznidazole (n = 5), but curative outcomes in all but one of the mice treated with fexinidazole sulfone 
(Fig. 4, Table 2). In C3H mice, infections with the JR strain display an extended acute phase, reaching chronic 
stage equilibrium later than in BALB/c mice29. For assessment of efficacy against chronic infections, treatment 
(5 days, 100 mg kg−1) was therefore delayed until day 161. In these circumstances, fexinidazole sulfone cured 5/5 
mice, with 3/5 cured in the case of benznidazole (Fig. 4c). Thus, T. cruzi infections are easier to cure in the chronic 
stage in two distinct murine/parasite models.
Figure 2. Effectiveness of nitroheterocyclic drugs in treating acute stage Trypanosoma cruzi infections 
when administered for 5 days at 50 mg kg−1 bid. (a) In vivo imaging of BALB/c mice infected with 
bioluminescent T. cruzi (CL Brener strain) and treated twice daily by the oral route with benznidazole (BZ), 
nifurtimox (NF), fexinidazole (FX), or fexinidazole sulfone (FXS). Treatment was initiated 14 days post-
infection (n = 6). Representative ventral images of 2 mice are shown for each drug, at various time points. NT, 
non-treated (vehicle only). Where necessary, to confirm curative outcomes, mice were immunosuppressed by 
cyclophosphamide treatment on days 28, 32 and 36 post-infection (underlined with a red bar). (b) Assessment 
of drug activity by ex vivo imaging. Representative images of organs/images isolated 50 days post-infection from 
NT (i), NF-treated (ii and iii), FX-treated (iv), and FXS-treated (v) mice. In the case of NF treatment, examples 
of cured (ii) and non-cured (iii) mice are illustrated.
www.nature.com/scientificreports/
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Pharmacokinetics and drug efficacy. To relate treatment outcomes to drug exposure, we assessed plasma 
concentrations of nitroheterocyclic drugs following single oral doses. For all compounds, the measured blood 
to plasma ratio was ~1, the fraction unbound in the in vitro assay media was > 0.9, and the fraction unbound 
in plasma was 0.7 for benznidazole, 0.5 for nifurtimox, and 0.4 for fexinidazole and fexinidazole sulfone. Given 
the low and comparable extent of binding, data comparisons were made using the total plasma concentration 
throughout.
Although there are no reports of differences in pharmacokinetics between acute and chronic infections, we 
investigated if the disparity in efficacy between the two stages could be linked to drug exposure. Benznidazole 
concentrations in mouse plasma were measured in uninfected mice, and during acute and chronic infections, 
after a single oral dose of 100 mg kg−1. Plasma concentrations were comparable under all conditions (Fig. 5a), 
suggesting that the reduced ability to cure acute stage infections was not attributable to factors that influence drug 
exposure (Fig. 5b).
Plasma concentrations of benznidazole reached a Cmax within 1 hour (Fig. 5b, Table 2), and then declined in 
a dose-dependent manner, dropping below the in vitro IC50 values after 6–12 hours (see also26). There was a clear 
association between benznidazole dose/exposure and effectiveness against both acute and chronic stage infec-
tions (Fig. 5c,d), although as noted above, the acute stage infections required a longer treatment duration.
When we investigated the PK properties of nifurtimox, we found that the Cmax and AUC were lower than for 
benznidazole, but plasma concentrations remained above the in vitro IC50 for longer (Fig. 6a). This may contribute 
Figure 3. Treatment of chronic (a) and acute (b) stage Trypanosoma cruzi infections with 30 mg kg−1 
benznidazole. Treatment of infected BALB/c mice (n = 6) with bioluminescent parasites (CL Brener strain) 
was initiated 124 or 126 days (chronic), or 14 days (acute) post-infection, once daily by the oral route, for the 
number of days indicated. Representative ventral images of the same pair of mice are shown for each drug, at 
various points post-infection. NT, non-treated (vehicle only). Where required to confirm curative outcomes, 
mice were immunosuppressed by cyclophosphamide treatment on days 42 and 46 (acute stage experiment), 
138, 142 and 146 (chronic stage experiment, 5 days treatment), and 154, 158 and 162 (chronic stage experiment, 
10 and 20 days treatment) (underlined with red bar). All mice scored as cured were bioluminescence negative 
by both in vivo and ex vivo imaging.
www.nature.com/scientificreports/
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Figure 4. Nitroheterocylic drug activity in other experimental models of Chagas disease. (a) BALB/c mice 
infected with bioluminescent T. cruzi JR strain were treated with benznidazole (BZ) or fexinidazole sulfone 
(FXS) 14 days post-infection. NT, non-treated (vehicle only). Drugs were administered orally, for 5 days at 
100 mg kg−1. FXS-treated mice were also immunosuppressed by cyclophosphamide treatment on days 32, 36 
and 40 to promote the reactivation of any residual parasites (underlined with red bar). BZ was non-curative 
in all cases, (n = 6), whereas 4/5 mice treated with FXS were judged parasite-free after both in vivo and ex 
vivo imaging. (b) C3H mice infected with bioluminescent JR strain were treated orally with BZ or FXS 14 
days post-infection, for 5 days at 100 mg kg−1. Where necessary, to confirm curative outcomes, mice were 
immunosuppressed by cyclophosphamide treatment on days 28, 32 and 36 post-infection (underlined with a 
red bar). BZ was non-curative (n = 5), whereas 4/5 mice treated with FXS were parasite-free after both in vivo 
and ex vivo imaging. (c) C3H mice, chronically infected with bioluminescent JR strain were treated orally with 
BZ or FXS for 5 days at 100 mg kg−1, commencing 161 days post-infection. Where required, cyclophosphamide 
treatment commencing on day 175, was used to promote reactivation. BZ-treatment cured 3/5 mice, whereas 
5/5 mice were cured with FXS. (d) Assessment of drug-activity by ex vivo imaging. Organs/tissues from mice 
treated in the acute stage were removed 50 days post-infection (Methods) from NT (i), BZ-treated (ii) and 
FXS-treated (iii and iv) mice. Organs/tissues are arranged as described in Figs 1a and 2b. In the case of FXS 
treatment, examples of non-cured (iii) and cured (iv) mice are illustrated.
Drug Cmax (μM) Tmax (h) AUC∞ (μM.h)
Benznidazole 
 10 mg kg−1 27.0 0.5 51.1
 30 mg kg−1 80.4 1.0 252
 100 mg kg−1 153 1.0 726
Nifurtimox 
 100 mg kg−1 52.5 1.0 179
Fexinidazole
 100 mg kg−1 0.30 (FX) 0.5 (FX) 0.94 (FX)
63.3 (FXSX) 0.5 (FXSX) 304 (FXSX)
103 (FXS) 2.2 (FXS) 1300 (FXS)
Fexinidazole sulfone
 100 mg kg−1 217 2.0 2010
Table 2.  Pharmacokinetic parameters following single dose administration to uninfected BALB/c 
(benznidazole) or Swiss outbred (nifurtimox, fexinidazole, fexinidazole sulfone) mice. Data for fexinidazole 
sulfone were taken from ref. 27. FX = fexinidazole; FXSX = fexinidazole sulfoxide; FXS = fexinidazole sulfone. 
Note that data for nifurtimox were generated in male mice and gender-related differences in PK properties 
cannot be ruled out.
www.nature.com/scientificreports/
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to the greater effectiveness of nifurtimox in reducing parasite burden when acute infections are treated with 50 mg 
kg−1 twice daily (Fig. 2), even though curative outcomes were limited. When fexinidazole plasma concentrations 
were assessed, the parent drug was detected at low concentrations (< 1 μ M), and only for a short period (Fig. 6b), 
however the two active metabolites, fexinidazole sulfoxide and sulfone30 were rapidly formed, with Cmax values of 
1–2 hours and 4–5 hours, respectively. Both metabolites remained above their in vitro IC50 for prolonged periods 
(12–14 hours for the sulfoxide, 24 hours for the sulfone). In mice where fexinidazole sulfone was administered 
directly, plasma concentrations reached a higher Cmax than achieved in fexinidazole-treated mice (217 vs 103 μ M), 
with a corresponding increase in the AUC (Table 2 and ref. 27). The prolonged exposure of the sulfone could in 
part explain why fexinidazole and fexinidazole sulfone have greater efficacy than benznidazole at the same dose 
(Table 1). The steep drop-off in efficacy against acute infections when the daily dose of fexinidazole sulfone was 
reduced from 100 to 50 mg kg−1, or when one daily dose at 50 mg kg−1 was administered instead of two, highlights 
the narrow window of drug exposure that determines treatment outcome in the 5 day regimen.
Discussion
Drug tests against chronic Chagas disease (both experimental and clinical) have been problematic, mainly 
because it is difficult to unambiguously confirm parasitological cure, even with PCR-based methodologies25. The 
dynamic, focal nature of the infection, and the extremely low parasite burden have been confounding factors23,29. 
Here, we used highly sensitive bioluminescence imaging coupled with cyclophosphamide-mediated immunosup-
pression to provide a reliable and flexible approach for systematic and comparative studies of drug efficacy. Our 
major finding is that nitroheterocyclic drugs cure T. cruzi infections in murine models more readily in the chronic 
stage than in the acute stage. This result is contrary to the widely held view that chronic infections in humans are 
intrinsically more difficult to treat12–21. We were able to exclude factors that influence plasma concentration for 
this differential drug efficacy, at least in the case of benznidazole (Fig. 5a). An alternative explanation could be 
that the pan-tropic nature of acute stage infections23 requires drugs to access every organ and tissue at levels suf-
ficient to produce a sterile cure. In chronic stage infections this might be easier to achieve, as the parasite burden 
is considerably lower and restricted to far fewer locations than in the acute phase. In mouse models, the colon 
and/or stomach are the major sites of parasite persistence, with other organs and tissues sporadically infected29.
Figure 5. Pharmacokinetic and cure rate data for benznidazole. (a) Plasma concentration versus time 
profiles of benznidazole following a single 100 mg kg−1 dose in uninfected (blue), acute (red) and chronic 
(green) stage infected BALB/c mice. The in vitro IC50 is shown by the dashed line. (b) Plasma concentration 
versus time profiles following single doses of 10 (green), 30 (red), and 100 (blue) mg kg−1 benznidazole in 
uninfected BALB/c mice. (c) Cure rates for benznidazole following 10 days (blue bar) and 20 days (red bar) 
treatment in chronic stage infected mice. (d) Cure rates for benznidazole following 10 days (blue bar) and 
20 days (red bar) treatment in acute stage infected mice. Because 100 mg kg−1 was ineffective with 10 days 
treatment in the acute stage, 30 and 10 mg kg−1 treatments were not tested (blue asterisks).
www.nature.com/scientificreports/
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Most in vivo drug testing has focused on acute stage infections, partly because it is more straightforward to 
monitor parasite burden31–34. From a clinical perspective however, the ability to cure chronic infections is the 
primary requirement35. Therefore, the differential stage-specific responses to nitroheterocyclic drugs highlight 
that chronic infections should be the major focus of studies in predictive animal models. In line with this, there is 
a need to systematically assess the extent to which drug-induced cure of chronic infections alleviates or prevents 
the development of cardiac pathology. There is strong evidence that successful treatment of acute stage infections 
is associated with improved prognosis36–39. However, with chronic infections, the evidence is less certain40. For 
example, in the BENEFIT trial, improvements in clinical outcomes related to cardiac cardiomyopathy were not 
observed 5 years after benznidazole therapy11, although aspects of this study are the subject of debate41–44. The 
availability of improved predictive models of chronic Chagas disease now provides an experimental platform to 
dissect the link between curative therapy and disease pathology. Data from such studies will be invaluable for 
informing and guiding the design of future clinical trials.
The current front-line drugs are used against acute stage infections, with cure rates of 80–90%19. Because of 
the complex and long-term nature of Chagas disease, and difficulties in establishing parasitological cure, there 
have been few rigorous studies to optimise treatment of chronic infections40. Therapeutic schedules have been 
Figure 6. Pharmacokinetic data for (a) nifurtimox, (b) fexinidazole, and (c) fexinidazole sulfone following 
a single 100 mg kg−1 dose (Methods). For fexinidazole (b), profiles for the metabolites fexinidazole sulfone 
(green) and fexinidazole sulfoxide (red) are shown together with the parent compound (blue). Data for 
fexinidazole sulfone reproduced from ref. 27. The in vitro IC50 values are shown by the dashed lines.
www.nature.com/scientificreports/
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based on regimens that proved relatively successful against the acute stage. However, a combination of severe 
side-effects and treatment length (60–90 days), in a context where the infection is often asymptomatic, can lead 
to compliance issues that impact on curative outcome. The data from this study, which demonstrate that chronic 
infections in mouse models are more easily cured by nitroheterocyclic drugs than acute stage infections (Table 1), 
suggest the possibility of reducing treatment duration and drug dose.
Although fexinidazole has been advanced into Phase II clinical trials against T. cruzi infection, the study was 
not completed because of tolerability issues45. Here, we demonstrate that fexinidazole and fexinidazole sulfone are 
more efficacious than both of the front-line drugs in murine models at equivalent doses, particularly in the acute 
stage. For example, 5 days treatment with 50 mg kg−1 bid, is almost always curative with fexinidazole and fexini-
dazole sulfone, but rarely so with benznidazole or nifurtimox (Table 1). Similarly, the effectiveness of the fexini-
dazole compounds is evident when administered in single daily doses of 100 mg kg−1. The PK studies suggest that 
this enhanced activity could be linked to higher and more prolonged plasma exposure than is achievable with 
either benznidazole or nifurtimox (Figs 5 and 6; Table 2), thereby allowing more effective targeting of parasites 
in a wider range of organs and tissues. However, these PK-based inferences are complicated by the fact that the 
trypanocidal properties of nitroheterocyclic drugs result from reactive metabolites generated within the parasite 
following nitroreductase-mediated activity8,46,47. We also cannot exclude the possibility of exposure changes with 
repeat administration, given that the PK studies were all single dose experiments. Whatever the determinant of 
efficacy, our results highlight the potential for reducing the treatment duration and/or therapeutic dose of fexini-
dazole and fexinidazole sulfone as a means of circumventing toxicity and compliance issues.
In summary, the application of highly sensitive imaging technology to predictive models of Chagas disease 
provides new insights into drug efficacy. Of particular importance is the finding that T. cruzi infections are more 
readily cured in the chronic stage. It will be important to establish if these observations are transferrable to a 
clinical setting.
Methods
Mice. Infection experiments were approved by the LSHTM Ethics Committee and performed under UK Home 
Office licence PPL70/8207. All methods and manipulations were performed in accordance with the requirements 
of this licence. Female BALB/c and C3H/HeN mice were obtained from Charles River (UK) and CB17 SCID mice 
were bred in-house. Mice were maintained as described previously23 and were aged 8–12 weeks when infected 
with bioluminescent CL Brener23 or JRcl4 strains29. Typically, 1 × 104 bloodstream trypomastigotes (BTs) in 0.2 ml 
PBS were used to infect SCID mice via intraperitoneal (i.p.) inoculation. Parasitaemic blood from these mice was 
obtained 2–3 weeks later and adjusted to 5 × 103 BTs ml−1 with PBS. Mice were then infected i.p. with 1 × 103 
BTs23. On occasions (~10%), infection with the JR strain led to a fatal outcome, prior to the initiation of treatment. 
These mice were not included in the data set (Table 1).
Parasites. T. cruzi strains CL Brener and JRcl4 were grown as epimastigotes at 28 °C26. Metacyclic trypomas-
tigotes were obtained by transfer to Graces-IH medium48 and harvested after 4–7 days. Tissue culture trypomas-
tigotes were obtained from infected L6 rat myoblasts29. Bioluminescent parasites expressing the firefly luciferase 
PpyRE9h gene22 were generated as described23,24.
Drug Treatment. Benznidazole, nifurtimox, fexinidazole and fexinidazole sulfone were synthesized by 
Epichem Pty Ltd., Australia, and prepared at 5 mg ml−1 in an aqueous suspension vehicle containing 5% (v/v) 
DMSO, 0.5% (w/v) hydroxypropyl methylcellulose, 0.5% (v/v) benzyl alcohol and 0.4% (v/v) Tween 80. Drugs 
were administered by oral gavage (~200 μ l), and vehicle only was administered to control mice. To detect residual 
infection, mice were immunosuppressed with cyclophosphamide (200 mg kg−1) by i.p. injection every 4 days for 
a maximum of 3 doses.
In vivo bioluminescence imaging. Mice were injected i.p. with 150 mg kg−1 d-luciferin in Dulbecco’s 
Ca2+/Mg2+ free PBS, then anaesthetized using 2.5% (v/v) isofluorane in oxygen. Images were obtained using an 
IVIS Lumina II system (Caliper Life Science) 10–20 minutes after d-luciferin administration. Exposure times var-
ied from 30 seconds to 5 minutes, depending on signal intensity. To estimate parasite burden, whole body regions 
of interest were drawn using LivingImage v4.3 to quantify bioluminescence expressed as total flux (photons/
second; p/s). The detection threshold was established from uninfected mice23. Animals with bioluminescence 
intensity below 5 × 103 p/s/sr/cm2 in both dorsal and ventral images following immunosuppression were desig-
nated cured, subject to confirmation by ex vivo assessment.
Assessing treatment efficacy by ex vivo imaging. Organs/tissue samples were assessed by ex vivo 
imaging23,25. Briefly, mice were injected i.p. with 150 mg kg−1 d-luciferin, then sacrificed by ex-sanguination under 
terminal anaesthesia 7 minutes later. They were perfused with 10 ml 0.3 mg ml−1 d-luciferin in PBS via the heart. 
Organs/tissues were excised, transferred to a Petri dish, soaked in 0.3 mg ml−1 d-luciferin, then imaged. Routinely, 
the carcass was assessed for bioluminescence associated with skin, skeletal muscle or remaining adipose tissue.
Pharmacokinetic analysis. Pharmacokinetic (PK) studies in non-infected mice conformed to the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and were approved by 
the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee. PK studies were conducted using 
infected and non-infected female BALB/c (benznidazole) or non-infected female (benznidazole, fexinidazole and 
fexinidazole sulfone) and male (nifurtimox) Swiss outbred mice. Drugs were administered by oral gavage. For the 
efficacy studies, blood samples (10 μ l) were collected from the tail vein into tubes containing MilliQ water (20 μ l) 
at 0.25, 0.5, 1, 2, 4, 6, 9, and 24 hours post-dose. Samples were subjected to 3x freeze/thaw cycles in liquid nitrogen 
before bioanalysis. The level of benznidazole in mouse blood was determined using UPLC-MS/MS (Waters Xevo 
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TQs) following protein precipitation with acetonitrile. Blood concentrations were converted to plasma concen-
trations using the measured blood to plasma ratio of ~1.
For the parallel PK studies, a maximum of two blood samples were collected from each mouse (with three 
mice per time-point) by submandibular bleed and terminal cardiac puncture into heparinised tubes. For benzni-
dazole, nifurtimox and fexinidazole, samples were collected for up to 24 hours post-dose, whereas for fexinidazole 
sulfone, samples were collected over 48 hours. Plasma was separated by centrifugation and stored at − 80 °C (max-
imum two weeks). For analysis, samples were thawed, proteins precipitated, and the supernatant analysed by LC/
MS with quantitation by comparison to a calibration curve prepared in blank plasma. Blood:plasma partitioning 
ratios in mouse plasma, and the fraction unbound in plasma and in vitro assay media binding, were assessed as 
described29.
For both efficacy and PK studies, plasma concentration versus time data were analysed by non-compartmental 
PK methods to obtain the maximum concentration (Cmax), the time to reach Cmax (Tmax), and the area under the 
plasma concentration time curve to infinity (AUC∞).
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